COMTESS

This brand name is authorized in Austria, Estonia, Finland, Croatia, Ireland, Lithuania, Netherlands, Poland, Romania, United Kingdom

Active ingredients

The drug COMTESS contains one active pharmaceutical ingredient (API):

1 Entacapone UNII 4975G9NM6T - ENTACAPONE

Entacapone belongs to a new therapeutic class, catechol-O-methyl transferase (COMT) inhibitors. It is a reversible, specific, and mainly peripherally acting COMT inhibitor designed for concomitant administration with levodopa preparations. Entacapone prolongs the clinical response to levodopa. Read about Entacapone

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N04BX02	Entacapone	N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BX Other dopaminergic agents
Discover more medicines within N04BX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1030273, 1064595, 1064607, 1363485
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 432229, 433250
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 22297, 22298
Country: IE	Health Products Regulatory Authority	Identifier(s): 18221
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1002975, 1008049, 1016715, 1028312
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 52035
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100160580
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W51543001, W51543002, W51543003, W51543004